Endogenous cannabinoid. Weak ligand for CB1 (Ki=23.8 µM) and CB2 (Ki=13.9 µM) receptor. Selective agonist at GPR55. Inhibits expression of fatty acid amide hydrolase (FAAH). Displays immunosuppressant and anti-inflammatory activity and reduces granuloma-induced hyperalgesia
Know who made it. See the evidence. Buy through one marketplace.
Endogenous cannabinoid. Weak ligand for CB1 (Ki=23.8 µM) and CB2 (Ki=13.9 µM) receptor. Selective agonist at GPR55. Inhibits expression of fatty acid amide hydrolase (FAAH). Displays immunosuppressant and anti-inflammatory activity and reduces granuloma-induced hyperalgesia
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
